Cited by 83Nanoparticle-Based Drug DeliveryAdvanced Drug Delivery SystemsPharmacology and Nanomedicine Research

Nanoparticle-Mediated Drug Delivery System for Cardiovascular Disease

Open access
Matoba, Tetsuya, Egashira, Kensuke·2014·International Heart Journal

Abstract

Administration of drugs and other therapeutic agents has been the central strategy of contemporary medicine for cardiovascular disease. The use of a drug delivery system (DDS) is always demanded to enhance the efficacy and safety of therapeutic agents, and improve the signal-to-noise ratio of imaging agents. Nano-scale materials modify in vivo drug kinetics, depending on (patho)physiological mechanisms such as vascular permeability and incorporation by the mononuclear phagocyte system, which constitute 'passive-targeting' properties of nano-DDS. By contrast, an 'active-targeting' strategy employs a specific targeting structure on nano-DDS, which binds to the target molecule that is specific for a certain disease process, such as tumor specific antigens and the induction of adhesion molecules. In this review, we summarize recent studies that applied nano-DDS for the diagnosis and treatment of cardiovascular disease, especially focusing on atherosclerosis and myocardial ischemia-reperfusion (IR) injury. Pathophysiological changes in atherosclerosis and myocardial IR injury are successfully targeted by nano-DDS and preclinical studies in animals showed positive effects of nano-DDS enhancing efficacy and reducing adverse effects. The development of nano-DDS in clinical medicine is keenly being awaited.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1536/ihj.14-150

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nano- medicine therapeutic approaches to overcome cancer drug resist- ance. Adv Drug Deliv Rev 2013; 65: 1866-79.

Cited by

Sorted by citations

Authors
Matoba, T., & Egashira, K.
Affiliations
Kyushu University (JP)
Venue
International Heart Journal
Published
2014
Volume
55
Issue
4
Pages
281-286
ISSN
  • 1349-2365 (ISSN-L)
  • 1349-3299
OpenAlex
W2094658016
Cited by
83
References
54
Citations by year
2026: 3 · 2025: 6 · 2024: 4 · 2023: 6 · 2022: 11 · 2021: 9 · 2020: 8 · 2019: 8 · 2018: 5 · 2017: 10 · 2016: 9 · 2015: 3 · 2014: 1
FWCI
0.52
Type
journal article
Language
en
Open access
Locations
  • International Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Pharmacology and Nanomedicine Research
Keywords
nanoparticle drug delivery, cardiovascular disease, atherosclerosis, myocardial ischemia-reperfusion injury, passive targeting, active targeting, vascular permeability, reticuloendothelial system, targeted drug delivery, nanomedicine
MeSH terms
Animals, Cardiovascular Agents, Cardiovascular Diseases, Equipment Design, Humans, Drug Delivery Systems, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review